Cell No. : Cell Name
RCB0881 : OCUB-M
update : 2023/02/16
|
| Comment | Same as OCUB-1, OCUB-F. |
| Comment from the depositor | Chromosome = pseudotetraploid. |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sawada, Tetsuji
|
| Originator |
Sawada, Tetsuji
|
| Year of deposit |
1993
|
| Original cell |
OCUB-1
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
53 years
|
| Tissue |
mammary gland, pleural fluid
|
| Disease name |
mammary tumor
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
chest wall, pleura
|
| Classification |
cancer
|
| Year of origin |
1988
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_1621
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS + 0.5mM Sodium Pyruvate
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
62-156(50) : /74(5),75(5),76(7),77(5),78(3),79(9)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
12
|
| User's Publication |
|
16729
Song J, Kobayashi Y, Asano Y, Sato A, Taniguchi H, Ui-Tei K.
Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo
Cancers (Basel)
2022
14(13):3162
PubMed ID: 35804932
DOI: 10.3390/cancers14133162
|
|
12142
Kazuyuki Kuramoto, Hiroyoshi Yamada, Takashi Shin, Yuki Sawada, Hidenori Azami, Tomohiro Yamada, Takeyuki Nagashima, Kei Ohnuki
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer
Bioorganic & Medicinal Chemistry
2020
PubMed ID: 32007387
DOI: 10.1016/j.bmc.2020.115307
|
|
11511
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature
2019
PubMed ID: 30971826
DOI: 10.1038/s41586-019-1103-9
|
|
11545
Uhr K, Prager-van der Smissen WJC, Heine AAJ, Ozturk B, van Jaarsveld MTM, Boersma AWM, Jager A, Wiemer EAC, Smid M, Foekens JA, Martens JWM.
MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.
PLoS ONE
2019
PubMed ID: 31063487
DOI: 10.1371/journal.pone.0216400
|
|
14384
Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M, Komohara Y.
High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer
Cancer Sci
2017
108(8):1693-1700
PubMed ID: 28574667
DOI: 10.1111/cas.13287
|
|
18180
Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Invest New Drugs
2014
32(1):14-24
PubMed ID: 23686707
DOI: 10.1007/s10637-013-9971-6
|
|
8492
Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M.
Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.
Breast Cancer Res. Treat.
2010
122:125-33
PubMed ID: 19763817
DOI: 10.1007/s10549-009-0545-4
|
|
3352
Sugimoto, Mayumi, Fujikawa, Akira, Womack, James E, Sugimoto, Yoshikazu
Evidence that bovine forebrain embryonic zinc finger-like gene influences immune response associated with mastitis resistance.
Proc Natl Acad Sci U S A
2006
103:6454-9
PubMed ID: 16611727
DOI: 10.1073/pnas.0601015103
|
|
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
DOI: 10.1002/ijc.11348
|
|
14333
Su GH, Song JJ, Repasky EA, Schutte M, Kern SE.
Mutation rate of MAP2K4/MKK4 in breast carcinoma
Hum Mutat
2002
19(1):81
PubMed ID: 11754110
DOI: 10.1002/humu.9002
|
|
5547
Orui H, Imaizumi S, Ogino T, Motoyama T.
Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report.
J Orthop Sci
2000
5(6):600-4
PubMed ID: 11180925
DOI: 10.1007/s007760070012
|
|
13694
Kawamoto M, Shichijo S, Imai Y, Imaizumi T, Koga T, Yanaga H, Itoh K.
Expression of the SART-1 tumor rejection antigen in breast cancer
Int J Cancer
1999
80(1):64-7
PubMed ID: 9935232
DOI: 10.1002/(sici)1097-0215(19990105)80:1<64::aid-ijc13>3.0.co;2-7
|
Back
Top
CELL BANK Website
